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Angiotensinogen Gene Promoter Haplotype and
Microangiopathy-Related Cerebral Damage
Results of the Austrian Stroke Prevention Study
Helena Schmidt, MD; Franz Fazekas, MD; Gert M. Kostner, PhD;
Cornelia M. van Duijn, PhD; Reinhold Schmidt, MD
Background and Purpose—Microangiopathy-related cerebral damage (MARCD) is a common finding in the elderly. It
may lead to cognitive impairment and gait disturbances. Arterial hypertension and age are the most important risk
factors. We assessed the association between MARCD and sequence alterations in the promoter region of the
angiotensinogen (AGT) gene.
Methods—We studied 410 randomly selected community-dwelling individuals aged 50 to 75 years. MARCD was defined
as early confluent or confluent white matter hyperintensities or lacunes on a 1.5-T MRI. The AGT promoter was
analyzed by temporal temperature gradient gel electrophoresis and automated sequencing.
Results—We detected 4 polymorphic sites, at positions 26, 220, 2153, and 2218. They created 5 haplotypes, which we
coded as A (26:g, 220:a, 2153:g, 2218g), B (26:a, 220:c, 2153:g, 2218:g), C (26:a, 220:c, 2153:a, 2218:g), D
(26:a, 220:a, 2153:g, 2218:g), and E (26:a, 220:a, 2153:g, 2218:a). MARCD was seen in 7 subjects (63.6%)
carrying 2 copies of the B haplotype (B/B), in 12 subjects (38.7%) carrying 1 copy of the B haplotype in the absence
of the A haplotype (B1/A2), but in only 70 subjects (19.0%) in the remaining cohort (P,0.001). The odds ratios for
the B/B and the B1/A2 genotypes were 8.0 (95% CI, 2.1 to 31.1; P50.003) and 1.8 (95% CI, 0.8 to 4.2; P50.14) after
adjustment for possible confounders.
Conclusions—The B haplotype of the AGT promoter in the absence of the wild-type A haplotype might represent a genetic
susceptibility factor for MARCD. (Stroke. 2001;32:405-412.)
Key Words: angiotensins n genetics n magnetic resonance imaging n small-vessel disease
Microangiopathy-related cerebral damage (MARCD) is acommon MRI observation in elderly persons and
includes white matter changes and lacunar infarcts.1,2 Al-
though these findings may be recognized in otherwise normal
individuals, they are likely to become associated with cogni-
tive impairment and gait disturbances as they progress.3,4
Identification of individuals prone to the development of such
brain lesions and early control of causal factors could reduce
the risk of these common clinical problems of the elderly.
Thus far, it is unclear which factors other than advancing age
and arterial hypertension predispose individuals to
MARCD.2–4 The significance of genetic influences was
demonstrated by an investigation of World War II veteran
twins. This investigation reported a probandwise concordance
rate for extensive white matter lesions of 61% in monozy-
gotic and of 38% in dizygotic twins compared with a
prevalence of 15% in the entire population. The estimated
heritability of lesion volume was 73%.5 The consistent
association between MARCD and arterial hypertension sug-
gests that genes involved in the regulation of blood pressure
may contribute to this strikingly high heritability.6,7
The renin-angiotensin system (RAS) is a major regulator of
blood pressure. Plasma angiotensinogen (AGT) synthesized
by the liver is processed to angiotensin II (Ang II) by the
serial action of renin and angiotensin-converting enzyme.
Importantly, the plasma level of AGT is rate limiting in this
cascade.8 Positive correlation between plasma AGT concen-
tration, RAS activity, and blood pressure in humans and in
animal models supports this assumption.8–11 Production of
AGT in the liver is regulated mainly at the transcriptional
level.11,12 Two common polymorphisms in the promoter
region at position 26:g3a and 220:a3c have been previ-
ously described and were shown to alter the transcriptional
efficiency of the AGT gene.11–16 Genetic linkage between the
AGT locus and essential hypertension has been repeatedly
reported,9,17 but there are also studies in Chinese and Finnish
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populations that do not confirm these results.18–20 Similarly,
conflicting data have been described for the association
between the T235 AGT gene variant and hypertension.9,21–27
These controversial findings suggest ethnic variation in the
genetics of hypertension, yet differences in the definition of
the phenotype may also be responsible for these
inconsistencies.
In the present study we investigated the association be-
tween AGT gene polymorphisms and MARCD in a cohort of
community-dwelling middle-aged and elderly individuals.
The study focused on variants in the promoter region of the
gene since they are likely to influence AGT expression and
may prove to be functionally important.
Subjects and Methods
Study Population
The study population consisted of participants of the Austrian Stroke
Prevention Study, a single-center, prospective, cohort study on the
cerebral effects of vascular risk factors in the normal elderly
population of the city of Graz, Austria. The study was approved by
the Medical Ethics Committee of Karl-Franzens University. Written
informed consent was obtained from all study participants. We
randomly selected 8193 individuals aged 50 to 75 years stratified by
sex and 5-year age groups from the official community register.
Between September 1991 and March 1994, individuals received a
written invitation containing a full description of the purpose of the
investigation to participate in the study. Overall, 2794 of the invited
subjects returned a card stating their willingness to participate.
Recruitment into the study was stopped after enrollment of 2000
eligible participants. They were all white and of Central European
origin. Individuals were excluded from the study if they had a history
of neuropsychiatric disease, including previous cerebrovascular at-
tacks and dementia, or an abnormal neurological status determined
on the basis of a structured clinical interview and a physical and
neurological examination. A random age- and sex-stratified sample
of 200 nonresponders was interviewed by telephone and did not
differ in terms of length of education, occupational status, and
history of vascular risk factors, including arterial hypertension,
diabetes mellitus, and cardiac disease. Every fourth study participant,
or in case of refusal the next participant, was invited to enter phase
II of the study, which included MRI and Doppler sonography. Since
1993 DNA samples of phase II subjects had been collected. From a
total of 498 phase II participants, 458 volunteered to undergo a MRI
study. The current study cohort consists of those 410 individuals who
underwent both MRI examination and genotyping of the AGT gene.
There were 214 women (52.2%) and 196 men (47.8%). The mean
age of this cohort was 60.166.0 years. The study sample did not
differ from the remaining Austrian Stroke Prevention Study cohort in
terms of age, sex, educational and occupational status, and risk
factors for stroke.
Vascular Risk Factors
The diagnosis of major risk factors for stroke, including arterial
hypertension, diabetes mellitus, and cardiovascular disease, was
determined by the history of the individual and appropriate labora-
tory findings. A detailed description of the laboratory methods used
and the definition of these risk factors are given elsewhere.28
DNA Analysis
Genomic DNA extracted from peripheral blood was polymerase chain
reaction (PCR) amplified with the following oligonucleotides: AGT-
PROM5: 59-GC-Clamp-CTTGGCCCCGACTCCTGCAAACT-39 and
AGTPROM3: 59-CCCCCGGCTTACCTTCTGCTGTA-39 in 40 cycles
consisting of 1 minute at 94°C, 1 minute at 65°C, and 2 minutes at 72°C.
The PCR products (354 bp long, containing a part of the AGT
promoter and exon 1, from 2268 to 141 nucleotide, as well as a
40-bp-long GC clamp) were genotyped by temporal temperature
gradient gel electrophoresis (TTGE) with the use of the Dcode
Universal mutation detection system (Bio-Rad Laboratories). TTGE
is a sensitive method for the detection of virtually all poly-
morphisms, whether new or already known, and their precise
combination within the amplified fragment in a single step without
the need for further processing of the samples by, eg, restriction
enzyme digestion.29 Melting domain map was calculated with the
MacMelt computer algorithm (Bio-Rad Laboratories). PCR products
were electrophoresed on 9% polyacrylamide gels containing 8 mol/L
urea at 130 V with a temperature gradient of 57°C to 66°C, at a
heating rate of 1.5°C/h. Heterozygous DNA samples were used as
positive controls on each gel to check gel resolution efficiency. At
least 3 samples within each of the 15 distinct banding pattern groups
seen on TTGE were sequenced on an ABI 373 automated sequencer
(Perkin Elmer/Applied Biosystems).
Magnetic Resonance Imaging
MRI was performed on 1.5-T superconducting magnets (Gyroscan S
15 and ACS, Philips) with the use of T2-weighted (repetition time,
2000 to 2500 ms; echo time, 30 to 60 ms) sequences in the transverse
plane. T1-weighted images (repetition time, 600 ms; echo time, 30
ms) were generated in the sagittal and transverse planes. Slice
thickness was 5 mm, and the matrix size used was 1283256 pixels.
All scans were read by an experienced investigator without knowl-
edge of the clinical and laboratory data. The scans were evaluated for
white matter hyperintensities (WMH) and lacunar lesions. WMH
were graded according to our scheme as absent, punctate, early
confluent, and confluent.30 Caps and periventricular lining were
disregarded because they probably represent normal anatomic vari-
ants.31,32 Lacunes were focal lesions involving the basal ganglia,
internal capsule, thalamus, or brain stem not exceeding a maximum
diameter of 10 mm. Assessment of intrarater variability for WMH
grading and for presence of lacunar lesions was done in a subset of
70 randomly selected study participants and yielded ß values of 0.90
and 0.86, respectively. After the scans were read, individuals were
considered to have MARCD if they presented with early confluent or
confluent WMH or lacunes or any combination of these findings.
Punctate WMH were not included in the definition of MARCD
because these foci cannot definitely be attributed to cerebral ische-
mia according to histopathological correlations.32
Statistical Analysis
We used the Statistical Package for Social Sciences (SPSS/PC1,
version 8.0.0; SPSS Inc) for data analysis. Categorical variables
among the genotypes were compared by the x2 test or by Fisher’s
exact test. Assumption of normal distribution for continuous vari-
ables was tested by Lilliefors statistics. Normally distributed vari-
ables were compared by 1-way ANOVA and nonnormally distrib-
uted variables by the Kruskal-Wallis test. To estimate the
relationship between genotype and MARCD, we first performed an
unadjusted comparison of the frequency of MARCD by genotypes.
Logistic regression modeling was then done to assess the relative
contribution of a given genotype on the presence of these brain
lesions. We considered the dichotomized variables sex, hyperten-
sion, diabetes, and cardiac disease, the categorical variable smoking,
and the continuous variables age, total cholesterol, and fibrinogen as
possible confounders in the model. The analyses were also done with
systolic and diastolic blood pressure in place of hypertensive status.
Odds ratios (ORs) and 95% CI were calculated from the b coeffi-
cients and their SEs.
Results
We screened a part of the AGT gene promoter and exon 1
(from 2268 to 141 nucleotide related to the transcription
start) for the presence of point mutations using TTGE in 410
elderly, neurologically asymptomatic subjects. TTGE showed
15 different banding patterns indicating the presence of 15
genotypes within this population. There were 5 banding
patterns containing 1 homoduplex band (homozygotes) and
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10 banding patterns containing 2 homoduplex and 2 hetero-
duplex bands (heterozygotes) (Figure 1). This is in accor-
dance with the presence of 5 alleles combined in 15 geno-
types. We designated the 5 alleles on the basis of their gel
positions as A, B, C, D, and E alleles. The frequencies of the
alleles A (wild-type) to E were 0.567, 0.151, 0.043, 0.138,
and 0.101, respectively. The alleles and genotypes were in
Hardy-Weinberg equilibrium (x2obt52.7, P.0.99; x2crit523.68,
df514). We sequenced at least 3 samples within each
genotype group. Samples with the C/C or D/D genotypes
were all sequenced because they could not be unequivocally
designated on the basis of TTGE alone. All samples within 1
TTGE banding pattern group showed identical results on
sequencing. Altogether we sequenced each allele at least 15
times (3 times in homozygous state and 12 times as a
component of a heterozygous genotype). We detected 4
polymorphic sites at positions 26:g/a, 220:a/c, 2153:g/a,
and 2218:g/a in our cohort. Respective allele frequencies
were 0.57 (26:g) and 0.43 (26:a), 0.81 (220:a) and 0.19
(220:c), 0.95 (2153:g) and 0.05 (2153:g), and 0.90
(2218:g) and 0.10 (2218:a). The alleles and the genotypes at
the single-nucleotide polymorphisms were in Hardy-
Weinberg equilibrium, as demonstrated by the respective x2obt
and probability value (26: x2obt50.05, P.0.95; 220:
x2obt50.12, P.0.90; 2153: x2obt50.25, P.0.98; 2218:
x2obt50.44, P.0.95; x2crit55.991, df52). Each of the 5 alleles
contained a distinct combination of these polymorphic nucle-
otides and represented a haplotype (Table 1). Except for these
polymorphisms, there was no deviation from the published
AGT promoter sequence.33
MARCD was seen in 89 subjects (21.7%). A total of 59
individuals (14.4%) had early confluent or confluent WMH,
16 (3.9%) had lacunar lesions, and 14 (3.4%) had both types
of brain abnormalities. Subjects with MARCD were older
(62.665.7 years versus 59.466.0 years; P,0.0001) and had
a higher frequency of hypertension (50.6% versus 27.5%;
P,0.0001), higher systolic (144.7622.8 versus
136.9619.3 mm Hg; P50.004) and diastolic (87.669.6 ver-
sus 85.1610.6 mm Hg; P50.015) blood pressure, and a
higher frequency of cardiac disease (49.4% versus 34.4%;
P50.009) than their counterparts without MARCD.
The frequency of MARCD in the different genotype
subsets defined by the single-nucleotide polymorphisms is
shown in Table 2. Only the 220:c allele in homozygotic state
was significantly associated with an increased prevalence of
MARCD (P50.017). A weak linear association between this
polymorphism and MARCD was also present (P50.04). The
association between the 26:a polymorphism and MARCD
was borderline (P50.054). The other 2 polymorphic sites
were not associated with MARCD.
Next we investigated the association of MARCD with the
15 genotypes reconstructed from the haplotypes. Overall,
there was a significant association between the genotypes and
MARCD (P50.017). Subsequently, we performed pairwise
comparisons between the A/A genotype as reference group
and the other genotypes to further elucidate their association
with MARCD (Figure 2). Homozygotes for the B haplotype
had the highest frequency of MARCD, while homozygotes
for the C, D, and E haplotype showed very similar MARCD
frequency as A/A carriers (Figure 2A). MARCD prevalence
was also similar in all A haplotype carriers, including those
with the A/B genotype (Figure 2B). However, there existed a
trend toward higher MARCD frequency in individuals with 1
copy of the B haplotype in the absence of the A haplotype
(B/C, B/D, B/E) (Figure 2C). The remaining genotypes, C/D,
C/E and D/E, had MARCD frequencies similar to those of the
wild-type A/A genotype (data not shown).
On the basis of these findings, we pooled the subjects into
3 investigational subsets. The first group consisted of the B
homozygotes (B/B subset). The second group consisted of
those B heterozygotes who carried the B haplotype in the
absence of the wild-type A haplotype (B/C, B/D, and B/E)
TABLE 1. Nucleotide Sequence at Polymorphic Sites in
the 5 Haplotypes
Position
Haplotypes
A B C D E
26 g a a a a
220 a c c a a
2153 g g a g g
2218 g g g g a
Figure 1. TTGE banding patterns of the
15 AGT promoter genotypes related to
the haplotypes. A detailed description of
TTGE conditions is given in Subjects and
Methods.
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(B1/A2 subset). The third group contained the remaining
genotypes (A/A, A/B, A/C, A/D, A/E, C/C, C/D, C/E, D/D,
D/E, and E/E) and was designated as the reference cohort (RC
subset). Distribution of demographics and vascular risk fac-
tors among the 3 investigational subsets is shown in Table 3.
Overall, MARCD was seen in 7 subjects (63.6%) in the
B/B group, in 12 subjects (38.7%) in the B1/A2 group, but
in only 70 subjects (19.0%) in the RC group (Fischer’s exact
test, P,0.001; Mantel-Haenszel test for linear association,
P,0.001). The age-adjusted ORs for MARCD relative to the
RC subset were 7.6 (95% CI, 2.1 to 27.7) in the B/B and 2.2
(95% CI, 1.0 to 4.9) in the B1/A2 subset.
To evaluate the extent to which the B1/A2 genotype is
associated with MARCD, we performed logistic regression
analysis. The AGT genotype remained a significant pre-
dictor of MARCD (P50.0035) after adjustment was made
for age, sex, hypertension, diabetes, cardiac disease, smok-
ing, plasma fibrinogen, and total cholesterol (Table 4). The
respective ORs for the B/B and B1/A2 genotypes re-
mained unchanged when systolic (OR, 8.6; 95% CI, 2.26 to
32.7; OR, 1.9; 95% CI, 0.84 to 4.3) or diastolic blood
pressure (OR, 8.6; 95% CI, 2.25 to 32.7; OR, 1.9; 95% CI,
0.83 to 4.3) levels instead of hypertension status were
included in the model.
TABLE 2. Association of MARCD With AGT Promoter Polymorphisms
Genotypes P* P†
Position 26 gg (n5131) ga (n5203) aa (n576)
MARCD 28 (21.4%) 37 (18.2%) 24 (31.6%) 0.054 0.16
Position 220 aa (n5267) ac (n5127) cc (n516)
MARCD 53 (19.8%) 28 (22.0%) 8 (50%) 0.017 0.04
Position 2153 gg (n5376) ga(n533) aa (n51)
MARCD 82 (21.8%) 7 (21.2%) 0 (0%) 0.868 z z z
Position 2218 gg (n5330) ga (n577) aa (n53)
MARCD 71 (21.5%) 17 (22.1%) 1 (33.3%) 0.878 z z z
*x2 test.
†Mantel-Haenszel test for linear association.
Figure 2. Frequency of MARCD among the
AGT promoter genotypes reconstructed from
the haplotypes. In each panel MARCD fre-
quencies are compared with wild-type A
homozygotes. A, Comparison with homozy-
gotes for the B, C, D, and E haplotypes. B,
Comparison with heterozygote A haplotype
carriers. C, Comparison with subjects carrying
at least 1 copy of the B haplotype in the
absence of the A haplotype. Probability values
represent x2 or Fisher’s exact test results.
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Finally, we investigated the association between MARCD
and the B haplotype in subgroups defined by age, sex, and
hypertension status. MARCD frequency in subjects aged #60
years was 22 (11.1%) in the RC, 4 (40%) in the B1/A2, and
4 (66.7%) in the B/B group (P50.001). The respective
frequencies were 48 (28.4%), 8 (38.1%), and 3 (69%) in
subjects aged .60 years (P50.09). MARCD prevalence in
normotensive subjects was 35 (13.8%) in the RC, 5 (29.4%)
in the B1/A2, and 4 (66.7%) in the B/B group (P,0.001).
The respective frequencies in the hypertensive group were 35
(30.7%), 7 (50%), and 3 (60%) (P50.06). The prevalence of
MARCD in men was 35 (20.0%) in the RC, 5 (35.7%) in the
B1/A2, and 4 (57.1%) in the B/B group (P50.03). Among
women, the respective frequencies were 35 (18.1%), 7
(41.2%), and 3 (75.0%) (P50.002).
Discussion
We report 4 new findings. First, we identified the presence of
5 novel haplotypes reconstructed from 4 polymorphisms at
the AGT gene promoter. Second, we found that the 220:c
allele, which was shown to alter transcriptional efficiency of
the AGT promoter in vitro,16 is significantly associated with
MARCD. Third, we described that 1 of the 5 haplotypes,
designated as the B haplotype (nucleotide sequence at poly-
morphic positions 26:a, 220:c, 2153:g, 2218:g) predicts
MARCD considerably better than the 220:c single-nucleo-
tide allele. Fourth, the association between the B haplotype
and MARCD was independent of hypertension. Our study
was conducted in a homogeneous European population,
making bias due to population admixture unlikely.
We found that homozygotes for the B haplotype had an
8-fold increased risk for MARCD. Persons carrying 1 copy
of the B haplotype in the absence of the A haplotype
showed a trend toward higher risk for MARCD. There was
a significant linear association between B haplotype copy
number and MARCD, suggesting a gene-dose effect. This
gene-dose effect could also be observed in the subgroups
of younger and older individuals, in men and in women,
TABLE 3. Demographics and Risk Factors Among the AGT Promoter Haplotype Subsets
Variable
Genotypes
P
RC
(n5368)
B1/A2
(n531)
B/B
(n511)
Age, y 59.965.98 62.866.1 61.166.8 0.042*
Male sex, n 175 (47.6%) 14 (45.2%) 7 (63.6%) 0.549*
Hypertension, n 114 (31.1%) 14 (45.2%) 5 (45.5%) 0.178†
Systolic blood pressure, mm Hg 138.0619.9 143.9624.2 141.4622.0 0.391*
Diastolic blood pressure, mm Hg 85.4610.4 87.6611.1 86.8610.1 0.5141*
Diabetes mellitus, n 21 (5.7%) 3 (9.7%) 0 (0%) 0.469†
Fasting glucose, mmol/L 5.1661.14 5.5062.03 4.7460.40 0.399*
Cardiac disease, n 132 (36.0%) 20 (64.5%) 2 (18.2%) 0.003†
Smoking
Ex-smokers, n 49 (13.4%) 2 (6.5%) 1 (9.1%)
Current smokers, n 112 (30.5%) 8 (25.8%) 4 (36.4%) 0.695†
Body mass index, kg/m2 26.563.6 26.763.5 25.262.8 0.622*
Triglycerides, mmol/L 1.6260.92 1.9161.58 1.3960.44 0.811*
Cholesterol, mmol/L 5.9161.00 6.2861.17 6.1561.17 0.041‡
LDL cholesterol, mmol/L 3.8660.92 4.2061.00 4.1660.99 0.076‡
HDL cholesterol, mmol/L 1.3360.42 1.2460.42 1.3460.34 0.833*
Fibrinogen, mg/dL 301.5679.3 308.6684.7 301.6660.5 0.503*
*Kruskal-Wallis test.
†x2 test.
‡One-way ANOVA.
TABLE 4. Independent Predictors for MARCD in the Logistic Regression Model
Variable SE df P OR 95% CI
AGT genotype 2 0.005
B1/B1 genotype 2.081 0.692 1 0.003 8.01 2.1–31.1
B1/A2 genotype 0.614 0.420 1 0.144 1.84 0.8–4.2
Age, y 0.077 0.022 1 0.001 1.08 1.03–1.13
Hypertension 0.818 0.265 1 0.002 2.26 1.35–3.81
Adjustment was made for diabetes, cardiac disease, smoking, fibrinogen, cholesterol, and sex.
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and also among hypertensive and normotensive subjects.
Given their relation to protein levels, promoter poly-
morphisms are expected to have strongest effects in
homozygotes and milder effects in heterozygotes. Our data
support the presence of a gene- dose effect only for the
haplotype but not for the single-polymorphic sites. Persons
carrying the B haplotype in combination with the wild-type
A haplotype did not show a higher risk for MARCD,
indicating that the A haplotype might protect against the
deleterious effect of the B haplotype. The observed asso-
ciation was not mediated by hypertension, since it re-
mained virtually unchanged when adjustment was made
for age and hypertension or for age alone.
With respect to the statistical assessment of the associ-
ation between the AGT genotypes reconstructed from the
haplotypes and MARCD, it is important to emphasize that
the relationship was significant when a single comparison
of MARCD frequency among the 15 genotypes was
performed. We used pairwise comparisons between the
wild-type A/A genotype and the other genotypes to further
explore the association of each genotype with MARCD.
We expected a priori that carriers of the B and the C
haplotypes have higher MARCD frequencies than carriers
of the other haplotypes. This was based on in vitro and in
vivo data describing functional importance for the 220:c
and the 26:a mutations,13–16 both of which are only present
in the B and C haplotypes. Our observation of a significant
association between the 220:c allele and MARCD lends
further support to this assumption. The results of the
pairwise comparisons are not statistically significant after
Bonferroni correction with the very conservative signifi-
cance level of 0.0036. Adjustment for multiple testing is,
however, difficult when haplotypes are studied because
these are statistically dependent observations as a result of
linkage dysequilibrium. It is noteworthy that the strength
of the association increased by using the haplotype in place
of the single-nucleotide markers, as expected if a true
causal relation is involved. Yet, despite the plausibility of
the association between the B haplotype and MARCD, we
cannot exclude with certainty that this is a chance finding.
At this point it is important to note that our results apply
strictly to a single cohort, and larger, probably concerted
studies are needed to confirm these findings. The current
investigation was exploratory. Overall, our findings show
that the haplotype allows a more sensitive analysis of the
association than the polymorphic sites alone. There are
several explanations for this observation. It may be that the
combination of the previously described sequence alter-
ations in the B haplotype is functionally important or that
the B haplotype captures an unknown sequence alteration
functionally related to MARCD. The B haplotype may also
be in linkage dysequilibrium, with a functional poly-
morphism underlying the association.
On the basis of in vitro and in vivo data, a causal
relationship between AGT genotype and hypertension
seems plausible.9 –27 However, we have seen that the B
haplotype is associated with MARCD independent of
arterial hypertension. This suggests that it may operate
through the local rather than through the systemic RAS.
Genetic variations at the AGT locus might alter tissue
AGT expression. In preeclampsia, the expression of AGT
in decidual arteries was associated with the T235 variant.34
It is noteworthy that a strong linkage dysequilibrium
between the B haplotype and the T235 variant existed in
our cohort. All B/B and 28 of the 31 B1/A2 subjects were
homozygous for the T235 allele. The remaining 3 B1/A2
subjects were heterozygous for the M235T polymorphism.
Conceivably, the association between the AGT B hap-
lotype and MARCD might be mediated by an altered
expression of AGT in the brain,35 which in turn leads to an
altered local availability of AGT. Studies investigating
AGT expression in the brain dependent on the haplotype
have been initiated in our laboratory. If tissue RAS activity
is also regulated by the AGT level, as is systemic RAS,
then changes in AGT concentration may result in a higher
level of Ang II at this site. It is known that Ang II acts on
a variety of cell types in the brain.36,37 In the present
context the effect of Ang II on vascular smooth muscle
cells is of particular interest. Ang II is a potent regulator of
vascular tone and can lead to vasoconstriction and vaso-
dilation in the cerebral arterioles, depending on the species
studied.38 – 43 Notably, MARCD was found to be related not
only to hypertension but also to intermittent hypotensive
episodes.6,7 Ang II promotes vascular smooth muscle cell
hyperplasia and hypertrophy.44 – 48 It was shown to enhance
the activity of NADH/NADPH oxidase and extracellular
superoxide dismutase activity in the vessel wall.49,50 It is
also thought to alter the production of extracellular matrix
proteins in the vessels.51,52 Therefore, alterations in the
local availability of Ang II might result in imbalance of
physiological processes such as brain perfusion, autoregu-
lation of cerebral blood flow, the oxidative state of the vessel
wall, or function of the blood-brain barrier. Each of these
processes might be involved in the development of MARCD.
In summary, we found that a certain haplotype of the
AGT gene is significantly associated with MARCD in a
community-dwelling cohort of elderly individuals. If
larger studies can replicate our results, then this haplotype
might serve as a genetic marker for the identification of
individuals prone to develop these lesions and their clinical
consequences. An association of small-vessel disease–
related cerebral damage with genetic variants in the RAS
system independent of arterial hypertension might not only
extend our etiologic understanding of these brain lesions
but might also point to possible favorable effects of drugs
acting on the RAS system beyond those expected from
lowering blood pressure alone.
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